As observed in early-phase trials in Japan (Hamanishi et al., 2015; Yamazaki et al., 2017), China (Huang et al., 2018), and Asia-Pacific regions (Tahara et al., 2018), hypothyroidism was one of the top 3 most common AEs with anti-PD-1/PD-L1 therapies. The gene discussed is CD274; the disease is hypothyroidism.